AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger
📰 source: theguardian_business · 💼 business
astrazeneca should ditch any idea of a $400bn mega-merger with bristol myers squibb, says this piece. soriot has credit in the bank: he fought off pfizer in 2014 and bought alexion for $39bn in 2021. but a bms deal would load on debt, inherit a patent cliff on cancer drug opdivo, and invite regulatory pushback. the market agrees: az shares fell nearly 9% on monday.
soriot insists he can still hit the 2030 revenue target of $80bn, even after a heart drug failed in late-stage trials, pointing to 20 high-value readouts due in 18 months. the article says plan a is simple: keep investing $50bn in us r&d and manufacturing, and don't gamble on financial engineering. the bms idea is out of character and should be dropped.
why it matters: a failed $400bn pharma mega-merger would distract astrazeneca from its proven pipeline strategy and could erode shareholder value.
source: theguardian_business
sentiment: -0.50 · impact: 0.70